ALTUS PHARMACEUTICALS INC.

Altus Pharmaceuticals is based out of Cambridge. Altus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of oral and injectable protein therapeutics for gastrointestinal and metabolic disorders. The company's products include ALTU-135, a Phase II completed clinical trial product is an orally-administered enzyme replacement therapy for the treatment of malabsorption due to exocrine pancreatic insufficiency; and ALTU-238, a Phase II completed clinical trial product is a crystallized formulation of human growth hormone (hGH) for the treatment of growth hormone deficiency in adults and hGH-related disorders. Its preclinical stage products comprise ALTU-237 for the treatment of hyperoxalurias and kidney stones; ALTU-236, which is designed to reduce the long-term effects associated with excess levels of phenylalanine; and ALTU-242 that is designed to reduce the long-term effects associated with excess levels of urate. The company has strategic alliance with Cystic Fibrosis Foundation Therapeutics, Inc. for the development of ALTU-135, as well as collaboration agreement with Genentech, Inc. to develop, manufacture, and commercializes ALTU-238; and Dr. Falk Pharma GmbH for commercializing ALTU-135 in Europe, the countries of the former Soviet Union, Israel, and Egypt. Altus Pharmaceuticals was incorporated in 1992.Whalewisdom has at least 67 Form 4 filings The firm has no submitted 13F filings and does not appear to be an investment advisor.